|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Volcano Corporation (Nasdaq: VOLC), a provider of intravascular ultrasound and functional measurement products to diagnose and treat heart disease. |
|---|---|
| Transferring Party | Novelis, Inc., a maker of ultrasonic visualization and therapy technology for minimally invasive diagnostic and therapeutic devices. |
| Sector | Medical Devices |
| Date | May 19, 2008 |
| Analysis Novelis' core product includes an image-guided crossing catheter that combines visualization, steerability and RF tissue ablation designed to permit Interventional Cardiologists to safely address cross chronic total occlusions in the coronary and peripheral arteries. The system is not yet approved for human use and has yet to be submitted to the FDA for regulatory clearance. Deal terms -- $12m plus $3m in earnouts. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |